Ayuob Nasra N, Murad Hussam A S, Ali Soad S
Department of Anatomy, Faculty of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia Department of Histology and Cytology, Mansoura University, Egypt.
Folia Histochem Cytobiol. 2015;53(1):35-48. doi: 10.5603/FHC.a2015.0005. Epub 2015 Mar 13.
Few oral antidiabetic drugs have been evaluated for their reproductive complication. This study aimed to evaluate the effect of metformin, pioglitazone and sitagliptin on the structure of male reproductive system through an immunohistopathological study.
Sprague-Dawley male rats were injected with streptozotocin. The diabetic rats were divided into four groups (n = 8/each group); diabetic control, metformin-, pioglitazone- and sitagliptin-treated groups in addition to a normal control group (n = 8). At the end of the experiment, blood samples were collected for biochemical assessment. Testis, epididymis and seminal vesicle were dissected and processed for histopathological examination using routine and immune-staining.
All drugs significantly (p < 0.05) decreased fasting blood glucose, glycated hemoglobin, total cholesterol, triglycerides and malondialdehyde compared to the diabetic control group. Metformin has induced the least pathologic changes on the structure of the testis, epididymis and seminal vesicle among the studied drugs. Metformin succeeded to restore weights of testis, epididymis and seminal vesicle as well as testosterone hormone level back to values of the NC group while the pioglitazone and sitagliptin failed to do that. A significant reduction (p < 0.05) in testicular ERa and ERb immunoexpression of pioglitazone-treated group as well as suppression of ERb and AR immunoreactivity in in epididymus and seminal vesicles of pioglitazone- and sitagliptin-treated rats were observed compared to the control animals.
Histological structure as well ER and AR expression in the system organs were negatively and significantly affected with all studied drugs. Metformin has the least effect on the structure of the studied male reproductive organs. Thus, pioglitazone and sitagliptin treatment should be avoided in young male diabetic patients.
很少有口服抗糖尿病药物对其生殖并发症进行过评估。本研究旨在通过免疫组织病理学研究评估二甲双胍、吡格列酮和西他列汀对雄性生殖系统结构的影响。
将链脲佐菌素注射到斯普拉格-道利雄性大鼠体内。糖尿病大鼠分为四组(每组n = 8);糖尿病对照组、二甲双胍治疗组、吡格列酮治疗组和西他列汀治疗组,此外还有一个正常对照组(n = 8)。实验结束时,采集血样进行生化评估。解剖睾丸、附睾和精囊,并使用常规和免疫染色进行组织病理学检查。
与糖尿病对照组相比,所有药物均显著(p < 0.05)降低了空腹血糖、糖化血红蛋白、总胆固醇、甘油三酯和丙二醛。在所研究的药物中,二甲双胍对睾丸、附睾和精囊结构的病理改变最小。二甲双胍成功地将睾丸、附睾和精囊的重量以及睾酮激素水平恢复到正常对照组的值,而吡格列酮和西他列汀未能做到这一点。与对照动物相比,观察到吡格列酮治疗组睾丸ERa和ERb免疫表达显著降低(p < 0.05),以及吡格列酮和西他列汀治疗的大鼠附睾和精囊中ERb和AR免疫反应性受到抑制。
所有研究药物均对系统器官的组织结构以及ER和AR表达产生了显著的负面影响。二甲双胍对所研究的雄性生殖器官结构的影响最小。因此,年轻男性糖尿病患者应避免使用吡格列酮和西他列汀治疗。